Recent aspects for disseminated carcinomatosis of the bone marrow associated with gastric cancer: What has been done for the past, and what will be needed in future?

Table 1 Levels of serum and/or urinary bone metabolic markers in patients with disseminated carcinomatosis of the bone marrow associated with gastric cancer

			Bone resorption markers			Bone formation markers
	Age	Sex	1CTP (4.5 mg/mL)2	NTx (urine) (< 89 nmol/L BCE/mmol/L Cre)2	DPD (urine) (< 7.6 nmol/L BCE/mmol/L Cre)2	BAP (< 20.9 μg/L)2	OC (< 13.0 ng/mL)2
Case report
Takeda et al[10]	87	F	-	14800	59	929	32
Hasuda et al[11]	39	M	19.5	-	-	-	-
Mizuno et al[12]	44	M	-	-	59	-	37
Our cases1
1	60	M	8.9	-	-	258	-
2	47	F	17.7	> 300	-	1260	-
3	74	F	8.0	-	-	78	-
4	54	M	9.7	-	-	55	-
5	58	M	6.7	-	-	96	-
6	47	F	-	-	-	275	-
7	58	M	13.2	-	-	159	-
8	78	F	26.5	> 300	-	429	-
9	67	F	6.7	175	-	63	-
10	71	M	14.4	> 300	-	421	-
11	53	F	9.9	235	-	468	-
12	70	M	-	20	-	62	-

¹Our 12 cases have not been published;

²Values in the parentheses indicate the normal range. 1CTP: C-terminal telopeptide of type I collagen; NTx: N-terminal crosslinking telopeptide of type I collagen; DPD: Deoxypyridinoline; BAP: Bone-specific alkaline phosphatase; OC: Osteocalcin.